PMID- 30383627
OWN - NLM
STAT- MEDLINE
DCOM- 20181114
LR  - 20240403
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 44
DP  - 2018 Nov
TI  - Nuanxin capsule for heart failure: A systematic review of randomized controlled 
      trials.
PG  - e12667
LID - 10.1097/MD.0000000000012667 [doi]
LID - e12667
AB  - OBJECTIVE: To assess the efficacy and safety of Nuanxin capsule for patients with 
      heart failure (HF). METHODS: A systematic literature search was performed in 6 
      databases: PubMed, EMBASE, Chinese National Knowledge Infrastructure (CNKI), 
      Wan-fang Data Information Site, Chinese BioMedical Database (CBM), VIP Chinese 
      Science and Technique Journals Database from the date of its inception up to 
      November 2016. Review Manager 5.2 software was used for assessment of risk of 
      bias, data synthesis and subgroup analysis. Begg and Egger tests were used for 
      assessing symmetries of funnel plot by software Stata 12.0. We conducted the 
      GRADE system to assess the quality of evidence. RESULTS: 12 trials involving 1418 
      participants were eligible. Compared with western medicine (WM) alone, Nuanxin 
      capsule plus WM showed statistical significance in total effective rate (RR 1.18, 
      95% condidence interval [CI] 1.13-1.25). According to subgroup analysis, the 
      6-months group and the 12-months group have better effect than the 3-month group. 
      As for 6-minute walking distance (6MWT), Nuanxin capsule plus WM compared with WM 
      has significantly increased walking distance (weighted mean difference [WMD] 
      42.56, 95% CI 34.27-50.85). Nuanxin capsule plus WM has significantly decreased 
      in mortality (RR 0.29, 95% CI 0.18-0.46) and re-admission rate (RR 0.48, 95% CI 
      0.39-0.60) compared with WM. Nuanxin capsule plus WM was beneficial for B-type 
      natriuretic peptide (-240.47, 95% CI -332.45-148.49). gger's and Begg's test 
      showed that there was no publication bias exist (P = .937). Influence analysis 
      showed that no single study affected the overall result. The GRADE quality of the 
      evidence was very low to Moderate across the different outcomes. CONCLUSIONS: 
      Despite of the apparently positive findings, we cannot draw a sound conclusion 
      that Nuanxin capsule has positive effect in patients with HF, because of the 
      insufficient evidence.
FAU - Wen, Junmao
AU  - Wen J
AD  - Guangzhou University of Chinese Medicine.
FAU - Cai, Yinhe
AU  - Cai Y
AD  - Guangzhou University of Chinese Medicine.
FAU - Sun, Weipeng
AU  - Sun W
AD  - Guangzhou University of Chinese Medicine.
FAU - Jiang, Chenguang
AU  - Jiang C
AD  - Guangzhou University of Chinese Medicine.
FAU - Lin, Tong
AU  - Lin T
AD  - Guangzhou University of Chinese Medicine.
FAU - Jiang, Nan
AU  - Jiang N
AD  - Guangzhou University of Chinese Medicine.
FAU - Luo, Chuanjin
AU  - Luo C
AD  - The First Affiliated Hospital of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Zhou, Chi
AU  - Zhou C
AD  - The First Affiliated Hospital of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Wu, Wei
AU  - Wu W
AD  - The First Affiliated Hospital of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Female
MH  - Heart Failure/*drug therapy/mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Patient Readmission/statistics & numerical data
MH  - Randomized Controlled Trials as Topic
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Walk Test
PMC - PMC6221618
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/11/02 06:00
MHDA- 2018/11/15 06:00
PMCR- 2018/11/02
CRDT- 2018/11/02 06:00
PHST- 2018/11/02 06:00 [entrez]
PHST- 2018/11/02 06:00 [pubmed]
PHST- 2018/11/15 06:00 [medline]
PHST- 2018/11/02 00:00 [pmc-release]
AID - 00005792-201811020-00005 [pii]
AID - MD-D-18-04159 [pii]
AID - 10.1097/MD.0000000000012667 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Nov;97(44):e12667. doi: 10.1097/MD.0000000000012667.